AstraZeneca’s (AZN) Hold Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of AstraZeneca (LON:AZN) in a report issued on Tuesday, Marketbeat reports. The brokerage currently has a £113 ($143.62) target price on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft restated a hold rating and set a £105 ($133.45) price target on shares of AstraZeneca in a research note on Tuesday, April 23rd. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of AstraZeneca in a research report on Thursday, April 4th. Barclays reissued an overweight rating and issued a £125 ($158.87) price objective on shares of AstraZeneca in a research report on Monday, April 8th. Berenberg Bank lifted their target price on shares of AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the company a buy rating in a report on Friday, May 3rd. Finally, BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of £118 ($149.97).

AstraZeneca Stock Down 0.9 %

Shares of LON AZN opened at £122.96 ($156.28) on Tuesday. The stock has a market capitalization of £190.59 billion, a PE ratio of 3,842.50, a P/E/G ratio of 0.95 and a beta of 0.16. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51. The firm has a fifty day moving average of £113.69 and a 200-day moving average of £106.82. AstraZeneca has a 52-week low of GBX 9,461 ($120.25) and a 52-week high of £124.88 ($158.72).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.